Search Results for "amyloidosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
